Filing Flows

Filing Flows › Companies › Vycor Medical › Cash flow

Vycor Medical cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$5K in Q2 2026 · $61K over twelve months

Operating cash flow−$5K
Free cash flow−$5K
Cash conversion cycle148 days

Analysis

In Q2 2026, Vycor Medical generated −$5K of operating cash flow. That is $51K less than in Q2 2025 ($47K).

Over the twelve months to Jun 30, 2026, operating cash flow was $61K; the largest uses were net borrowing (+) / repaid (−) ($62K), other investing ($2K); besides operations, cash came from other financing ($59K), asset & business sales ($2K); the cash balance rose by $59K.

Operating cash flow was −$5K against net income of −$22K. The largest differences: payables +$21K, prepaid and other assets +$18K, depreciation & amortization +$15K.

Its cash conversion cycle was 148 days (receivables 43 + inventory 230 − payables 125).

Free cash flow

Vycor Medical: free cash flow by quarterVycor Medical: free cash flow by quarter$10KQ3 2024−$38KQ4 2024−$27KQ1 2025$47KQ2 2025−$72KQ3 2025$38KQ4 2025$99KQ1 2026−$5KQ2 2026
Operating cash flow less capital spending.
Vycor Medical: operating cash flow against capital spendingVycor Medical: operating cash flow against capital spendingOperating cash flowCapital spending$10K$0Q3 2024−$38K−$2Q4 2024−$27K$0Q1 2025$47K$0Q2 2025−$72K$1Q3 2025$39K$2KQ4 2025$99K$0Q1 2026−$5K$0Q2 2026
Latest (Q2 2026): Operating cash flow −$5K, Capital spending $0.

Capital allocation, year by year

Vycor Medical: where the cash came from (up) and went (down), by fiscal yearVycor Medical: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingAsset salesCapital spendingFY2021: Operating cash flow $21KFY2021: Net borrowing $59KFY2021: Capital spending −$38K$80KFY2021FY2022: Operating cash flow −$217KFY2022: Net borrowing −$7KFY2022: Capital spending −$3KFY2022FY2023: Operating cash flow $29KFY2023: Net borrowing $211FY2023: Capital spending −$9K$30KFY2023FY2024: Operating cash flow $60KFY2024: Net borrowing −$8KFY2024: Asset sales $1KFY2024: Capital spending −$5K$61KFY2024FY2025: Operating cash flow −$13KFY2025: Net borrowing −$1KFY2025: Asset sales $1KFY2025: Capital spending −$5K$1KFY2025
Over these 5 years operating cash flow totalled −$120K; the largest uses were operating cash flow ($230K) and capital spending ($61K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$159K
Debtnone
Net cash$159K
Cash runway8.2 years

Vycor Medical is burning cash: its operations consume cash, a free cash flow of −$19K a year at the current rate against $159K of cash and investments: a runway of about 8.2 years before any new financing.

Where the cash came from and went

Vycor Medical: sources (+) and uses (−) of cash, Q2 2026Vycor Medical: sources (+) and uses (−) of cash, Q2 2026Other financing−$45KNet borrowing (+) / repaid (−)$35KCash drawn (+) / kept (−)$15KOperating cash flow−$5KAsset & business sales$342Not reconciled$20
Vycor Medical: sources (+) and uses (−) of cash, TTM to Q2 2026Vycor Medical: sources (+) and uses (−) of cash, TTM to Q2 2026Net borrowing (+) / repaid (−)−$62KOperating cash flow$61KCash drawn (+) / kept (−)−$59KOther financing$59KAsset & business sales$2KOther investing−$2KNot reconciled$20

From profit to cash

Vycor Medical: net income to operating cash flow, Q2 2026Vycor Medical: net income to operating cash flow, Q2 2026Net income−$22KDepreciation & amortization$15KReceivables−$8KInventory−$10KPayables$21KAccrued liabilities$3KPrepaid and other assets$18KOperating cash flow−$5K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 202643230125148
Q1 20264118495130
Q4 202560184100144
Q3 202547241151137
Q2 20254018715472
Q1 20254918618155
Q4 20244926523777
Q3 202458507382183

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Cash drawn (+) / kept (−)Free cash flow
Q2 2026−$5K—$35K$15K−$5K
Q1 2026$99K—−$15K−$87K$99K
Q4 2025$39K−$2K−$15K−$23K$38K
Q3 2025−$72K−$1−$22K$35K−$72K
Q2 2025$47K—−$5K−$39K$47K
Q1 2025−$27K—−$18K$45K−$27K
Q4 2024−$38K$2−$14K$52K−$38K
Q3 2024$10K—−$28K−$38K$10K

Vycor Medical: income statement and cash flow

Vycor Medical, Q2 2026: revenue $418K (-16% year over year), operating margin 1.6%. The chart follows the revenue to costs, profit and cash.

Vycor Medical: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.